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Abstract
Background: To our knowledge, the Alberta Moving Beyond Breast Cancer (AMBER) Study is the first and only
prospective cohort study of breast cancer survivors that includes objectively-measured physical activity (PA),
sedentary behavior, health-related fitness (HRF), and biologic mechanisms focused on understanding breast cancer
outcomes. The purpose of the present study was to report on the feasibility of recruitment, baseline measurement
completion, and the representativeness of the first 500 participants.
Methods: AMBER is enrolling newly diagnosed stage I (≥T1c) to IIIc breast cancer survivors in Alberta, Canada.
Baseline assessments are completed soon after diagnosis and include cardiorespiratory fitness, musculoskeletal
fitness, body composition, objective and self-reported PA and sedentary behavior, lymphedema, and blood
collection.
Results: Between July 2012 and November 2014, AMBER recruited its first 500 participants from a pool of 1,447 (35 %)
eligible breast cancer survivors. Baseline HRF assessments were completed on ≥85 % of participants with the exception
of upper body strength. Collection of ≥4 days/week of monitoring for the Actigraph GT3X® and ActivPAL® were
obtained from 90 % of participants. Completion rates were also high for blood (99 %), lymphedema (98 %), and
questionnaires (95 %) including patient-reported outcomes and correlates of exercise. The first 500 participants in
AMBER are an average age of 56 years, 60 % are overweight or obese, and 58 % have disease stage II or III.
Conclusion: Despite the modest recruitment rate and younger age, AMBER has demonstrated that many newly
diagnosed breast cancer survivors are willing and able to complete a wide array of sophisticated and physically
demanding HRF and PA assessments soon after diagnosis. AMBER is a unique breast cancer survivor cohort that may
inform future randomized controlled trials on lifestyle and breast cancer outcomes as well as PA behavior change in
breast cancer survivors. Moreover, AMBER may also inform guidelines on PA, sedentary behavior, and HRF for
improving breast cancer outcomes and survivorship.
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Background
Breast cancer is a major disease in Canada with 25,000
women expected to be diagnosed in 2015 and 5,100
expected to die from the disease [1]. Over their lifetime,
Canadian women have a 1 in 9 chance of developing
breast cancer and a 1 in 30 chance of dying from the
disease [1]. Early detection and improved treatments have
resulted in a 5-year relative survival rate of 88 % [1] across
all stages; and over 95 % for early stage disease. In 2009,
there were approximately 157,380 female breast cancer
survivors in Canada diagnosed within the past 10 years
[1]. Extrapolating beyond 10-year survivorship [2], there
are likely over 250,000 breast cancer survivors in Canada.
Unfortunately, surviving breast cancer often requires
difficult and prolonged medical treatments that can last
from several months to many years. Multimodal therapy
for breast cancer often includes surgery, radiation therapy,
chemotherapy, hormone therapy, and/or biologic therapy.
Not surprisingly, breast cancer and its treatments have a
negative effect on the health and well-being of breast can-
cer survivors, especially the physical and functional as-
pects of quality of life [3]. For example, breast cancer
survivors are at increased risk of a recurrence, second can-
cers, cardiac dysfunction, weight gain, bone loss, lymph-
edema, arthralgias, cognitive dysfunction, menopausal
symptoms, fatigue, and psychosocial distress [3].
Physical activity (PA) and health-related fitness (HRF)
improve many outcomes for breast cancer survivors,
however, limited research has focused on recurrence
and survival. A recent systematic review [4] identified
22 studies on this topic, although only 9 assessed post-
diagnosis PA. Compared to the lowest level of post-
diagnosis PA, the highest level of PA was associated
with a hazard ratio of 0.52 (95 % CI = 0.43–0.64) for
all-cause mortality, 0.59 (95 % CI = 0.45–0.78) for
breast cancer-specific mortality, and 0.79 (95 % CI =
0.63–0.98) for breast cancer events. The only HRF par-
ameter that has been regularly examined is body mass
index (BMI). A recent systematic review [5] of 79 stud-
ies reported that for BMI assessed within 12 months of
diagnosis, the relative risk for obese women was 1.23
(95 % CI = 1.12–1.33) for all-cause mortality and 1.25
(95 % CI = 1.10–1.42) for breast cancer-specific mortal-
ity. Associations were even stronger for BMI assessed
at least 12 months after diagnosis, suggesting that the
relative importance of HRF parameters for breast can-
cer outcomes may vary over the cancer trajectory.
Despite these promising findings, these studies are
limited because few were originally designed as breast
cancer survivor cohorts and none have focused on PA
and HRF. Consequently, these studies have relied on
basic self-reported measures of PA and simple self-
reported or objective measures of height and weight.
The studies lack objective measures of PA and sedentary
behavior, objective assessments of key HRF parameters
(e.g., cardiorespiratory fitness, musculoskeletal fitness,
body composition), biomarkers, and/or standardized as-
sessment time points.
We are currently conducting the Alberta Moving Beyond
Breast Cancer (AMBER) Study which, to our knowledge, is
the first and only prospective cohort study designed specif-
ically to examine the role of PA, sedentary behavior, and
HRF in breast cancer survivorship from the time of diagno-
sis and for the balance of life [6]. The overall primary aim
of AMBER is to examine the associations and mechanisms
linking objectively measured PA, sedentary behavior, and
HRF with breast cancer outcomes. AMBER includes many
features designed to overcome previous methodological
limitations including objective measures of PA and seden-
tary behavior, a comprehensive assessment of HRF parame-
ters, and blood collection at multiple standardized time
points across the breast cancer trajectory. Given the timing
of recruitment (soon after diagnosis) and the comprehen-
sive and physically demanding nature of the assessments,
the issue of feasibility was of paramount importance. Thus,
the primary purpose of the present paper was to report on
the feasibility and challenges of recruitment and baseline
measurement completion for the first 500 participants in
AMBER. A secondary purpose was to describe the charac-
teristics of the first 500 participants and compare their rep-




AMBER was approved by the Health Research Ethics Board
of Alberta: Cancer Committee and all participants provide
written informed consent. AMBER is a prospective cohort
study of newly diagnosed breast cancer survivors in Al-
berta, Canada. Assessments are made at baseline, 1, 3, and
5 years follow-up and include clinic-based and patient-
reported measures. The goal is to complete all baseline as-
sessments before any neoadjuvant or adjuvant therapy,
however, women may complete baseline assessments after
receiving up to 1 cycle of chemotherapy or 2 weeks (10
fractions) of radiation therapy. For women receiving sur-
gery as their first treatment, baseline assessments are gener-
ally completed within 90 days of surgery. The baseline
blood draw is generally performed pre-surgically in Calgary
because of an existing biospecimen banking program and
post-surgically in Edmonton.
Study population
Eligibility for AMBER includes: (1) histologically-confirmed
stage 1 (≥T1c) to stage IIIc breast cancer, (2) females be-
tween 18 and 80 years old, (3) completion of the revised
Physical Activity Readiness Questionnaire for Everyone
(rPAR-Q+) [7] and the electronic Physical Activity
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Readiness Medical Examination questionnaire (ePARmed-
X+) [7], (4) living in Edmonton or Calgary (or surrounding
areas), (5) ability to complete questionnaires in English, and
(6) not pregnant. We restricted our sample to ≥T1c tumor
stage because of our focus on breast cancer recurrence and
survival.
Recruitment
In Calgary, Alberta Health Services has developed the
comprehensive biospecimen rapid ascertainment method
(CoBRA) in conjunction with the Alberta Cancer Research
Biobank (ACRB). This method uses a population-based
sampling approach to identify all breast cancer cases prior
to surgery. All newly diagnosed women are contacted by
the ACRB to provide a pre-surgical blood and tumour tis-
sue sample. If consent is obtained, their blood and tissue
samples are stored for future research purposes. At the
same time, they are asked if they consent to be contacted
about future research. If this consent is obtained, an
AMBER recruiter contacts the individual by telephone to
recruit them prior to their treatment consultation. Those
women who agree to participate are emailed a letter of in-
vitation, information brochure, and consent form. The
rPAR-Q+ is then administered by telephone by a Canadian
Society for Exercise Physiology Certified Exercise Physiolo-
gist® (CSEP-CEP) prior to fitness testing.
In Edmonton, breast cancer survivors are recruited in
person from the Cross Cancer Institute. All newly diag-
nosed breast cancer survivors are reviewed for AMBER
eligibility during the New Patient Breast Clinic. If eli-
gible, they are approached about AMBER by their treat-
ing oncologist during their treatment consultation. If
interested, an AMBER recruiter then meets with pro-
spective participants to explain the study and provide
them with an information brochure. Participation is con-
firmed during a follow-up telephone call and the consent
form and rPAR-Q+ are completed during the first day of
testing.
Measurement procedures
Edmonton participants are assessed at the Cross Cancer
Institute and Behavioral Medicine Fitness Center at the
University of Alberta. Calgary participants are assessed
at the Human Performance Laboratory and the REACH
Center in the Faculty of Kinesiology at the University of
Calgary. The assessments are scheduled for 1 or 2 clinic
visits depending on participant preference and logistical
issues. Single day clinic visits are split into morning and
afternoon assessments to avoid undue fatigue. The as-
sessments include: (1) questionnaires, (2) completion of
HRF testing including DXA scans, (3) lymphedema/
upper body function measurements, (4) blood draw, and
(5) training in the use of the accelerometers and activity
monitor logs to complete a week-long assessment of
objective PA and sedentary behavior. The measures in
the AMBER Study have been described in detail previ-
ously [6] and are briefly summarized here.
Measures
Blood collection
The baseline blood draw is completed after an overnight
fast of at least eight hours although unfasted bloods are
permitted in some circumstances. A 60 ml sample is
taken at baseline and 30 ml samples at 1 and 3 years
follow-up. The samples are processed with 5 aliquots (2
buffy coat and 3 serum) stored for the ACRB and the
remaining aliquots available for our study for the bio-
marker assays. For this study, we are storing 20 aliquots
per person per blood draw (4 serum, 12 plasma, 4 buffy
coat). A complete blood collection, processing, shipping
and storage protocol has been developed to ensure
standardization of the procedures for the bloods at the
collection sites in Calgary and Edmonton. The aliquoted
blood samples are stored in our–86 °C freezers and
long-term storage is in Calgary.
Health and lifestyle questionnaires
Participants complete 4 questionnaire packages consist-
ing of: (1) a Baseline Health Questionnaire which in-
cludes demographic characteristics, menopausal status,
menstrual and reproductive history, exogenous hormone
use history, personal health history, medication history,
vitamin and supplement history, family history of cancer,
and smoking and alcohol drinking histories; (2) the Past
Year Physical Activity Questionnaire [8], (3) the Canad-
ian version of the US National Cancer Institute’s Diet
History Questionnaire [9], and (4) a General Health
Questionnaire that includes health-related quality of life,
symptoms, psychosocial outcomes, the theoretical deter-
minants of PA, and a sedentary behavior questionnaire.
Objective measures of physical activity and sedentary
behavior
PA is measured objectively using the Actigraph GT3X®
(Actigraph, LLC, Pensacola, FL). This small and light
weight device is a highly sensitive instrument that re-
cords acceleration using a tri-axial accelerometer. Partic-
ipants wear the monitor on their right hip attached by
an elastic belt during all waking hours for 7 consecutive
days. Participants also record the time they put on and
take off the monitor each day. The participants are given
these accelerometers after their HRF assessments and
are trained in their use as well as in the use of the daily
recording log.
Sitting time is assessed by the activPAL® inclinometer
(PAL Technologies, Glasgow, Scotland). The activPal®
classifies free-living activity into time spent sitting,
standing and walking. This information can be used to
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estimate daily energy expenditure and changes in the
free-living activity profile. The activPAL® is worn on the
anterior thigh. It provides accurate information about
posture (sitting, lying, standing and stepping) and transi-
tions between postures as well as raw accelerometer
count information [10]. For the current report, we de-
fined completion of the activity monitoring devices as
the collection of ≥4 days of monitoring.
Health-related fitness assessments
The HRF assessments are performed by CSEP-CEPs
using standardized testing protocols and the same equip-
ment at both sites. Complete description of the HRF as-
sessment protocols has been previously published [6].
The assessments are typically completed in the following
order: resting blood pressure and heart rate; body com-
position (dual x-ray absorptiometry, body mass, height,
waist and hip circumferences); abdominal endurance
(curl-ups), sit and reach flexibility, balance, grip strength,
cardiorespiratory fitness (graded treadmill exercise com-
bined with metabolic measurements that included sub-
maximal heart rate, blood pressure and ratings of
perceived exertion, ventilatory threshold, VO2peak and
recovery heart rate); and upper and lower body muscular
strength and endurance (chest and leg press predicted 1
repetition maximum and multiple repetition maximum).
Adequate recovery time, nutrition and hydration is pro-
vided between tests. The upper and lower body strength
measures are performed either on the same day after
approximately 2 h of full recovery or on a separate day.
The total HRF assessment time is approximately 2.5 to
3 h split over the morning and afternoon or over 2 sep-
arate days.
Upper body functioning
Lymphedema is assessed both by self-report and by clin-
ical examination. Arm volume is measured objectively
using the Perometer® (Perosystems, Germany). The
measurement of shoulder range of motion includes active
and passive shoulder movements and measurements of
forward flexion, abduction, internal rotation, external ro-
tation and horizontal abduction movements. Arm func-
tion is assessed using the Disabilities of the Arm,
Shoulder and Hand scale (DASH) [11]. The presence of
upper and lower extremity peripheral neuropathy is
assessed by self-report and objective measures of sen-
sorimotor function, strength and balance testing.
Results
Flow of the first 500 participants through the baseline as-
sessment in AMBER is presented in Fig. 1. Between July
2012 and November 2014, we screened 5,265 breast cancer
survivors of which 1,447 (27 %) were eligible. The most
common reasons for ineligibility were unavailability
through the ACRB (n = 1,960; 37 %), incorrect disease stage
(n = 844; 16 %), and medical/age issues (n = 463; 9 %). Of
the 1,447 eligible, 500 (35 %) were recruited to the study
and completed at least some baseline assessments. The
most common reasons for refusal were being over-
whelmed/too sick (n = 297; 21%), not interested (n = 287;
20 %), and out of town/distance (n = 190; 13 %). Quarterly
accrual to the study overall and by center is depicted in
Fig. 2. After an initial 6-month ramp-up period, AMBER
has been recruiting approximately 20 breast cancer survi-
vors per month with roughly equal accrual in Edmonton
and Calgary.
Table 1 reports the baseline assessment completion
rates overall and by center. For our primary exposure of
cardiorespiratory fitness, 431 of the 500 participants
(86.2 %) were able and willing to perform the treadmill
test sufficiently to obtain a direct or estimated measure
of VO2max. The primary reasons for not completing the
cardiorespiratory fitness test were safety issues such as
the presence of cardiovascular risk factors (n = 42; 8.4 %)
or musculoskeletal problems such as knee pain or ankle
injury (n = 19; 3.8 %). All other secondary HRF expo-
sures were completed by over 85 % of participants with
the exception of upper body strength and endurance.
The HRF assessment completion rates were comparable
between the 2 centers with the exception of the muscu-
lar strength and endurance measures, which were com-
pleted at a lower rate in Calgary.
The baseline assessment completion rates for lymph-
edema, upper arm function, peripheral neuropathy, and
blood collection were over 98 % and were comparable
between centers. The relative proportion of blood draws
that were performed pre-surgically versus post-surgically
differed by center because of the difference in recruit-
ment methods used within each center. The question-
naires were completed by approximately 95 % of
participants. Useable data of ≥4 days/week of monitoring
for the Actigraph GT3X® and activPAL® were obtained
from approximately 90 % of participants with slightly
lower rates in Calgary.
Table 2 reports some of the baseline characteristics of
the first 500 participants overall and by center. The aver-
age age is 56 years (SD = 11), 73 % are married, 77 % have
some postsecondary education, 51 % have an annual fam-
ily income ≥ $100,000, 84 % are Caucasian, and 39 % are
premenopausal. In addition, 60 % are overweight or obese
and 26 % have a family history of breast cancer. The distri-
bution of disease stage is 42 % stage 1 (≥T1c), 49 % stage
II, and 9 % stage III. There are few meaningful differences
between the centers.
Discussion
AMBER is a unique breast cancer survivor cohort study fo-
cused on the role of PA, sedentary behavior, and HRF in
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breast cancer survivorship. The eligibility rate for AMBER
has been 27 %, largely because of challenges in screening
women through the ACRB in Calgary, restrictions on dis-
ease stage, and medical/age issues. Some of the challenges
of screening through the ACRB in Calgary include women
declining to donate blood, opting out of being contacted
for future research, or not giving consent for their blood to
be used. AMBER is benefiting from an existing infrastruc-
ture in Calgary for obtaining pre-surgical blood and tissue
samples, however, this infrastructure also restricts the num-
ber of eligible participants since only women who have
consented to be contacted for future research after they
have donated a blood sample are eligible for AMBER. Large
numbers of women were also ineligible because of our
disease stage restriction to ≥ T1c, however, we felt this
restriction was necessary given our focus on recur-
rence and survival. Finally, women in poor health or
over the age of 80 were often ineligible because of the
requirement of maximal fitness testing. The only
change in eligibility we have made in AMBER since its
inception is to remove the restriction of a previous
cancer.
Fig. 1 Flow of the first 500 participants through baseline assessment in the AMBER Study, Alberta, 2012–2014
Fig. 2 Number of women recruited each quarter between July 2012
and November 2014 overall and by center for the first 500
participants in AMBER. Note: The 500th participant was recruited in
November 2014. 1st quarter = January to March; 2nd quarter = April
to June; 3rd quarter = July to September; 4th quarter = October
to December
Courneya et al. BMC Cancer  (2016) 16:481 Page 5 of 9
The first 500 participants in AMBER were recruited
over a 29 month period with a stable accrual rate of ap-
proximately 20/month. The overall recruitment rate is
35 %, which is comparable to other breast cancer sur-
vivor cohort studies focused on lifestyle, health, and can-
cer outcomes. For example, the Pathways Study [12]
recruited 37 % of eligible breast cancer survivors within
an average of 2 months of diagnosis; the Health, Eating,
Activity and Lifestyle (HEAL) Study [13] recruited 39 %
of eligible breast cancer survivors within 1 year of diag-
nosis; and the Life After Cancer Epidemiology (LACE)
Study [14] recruited 41 % of eligible breast cancer survi-
vors within an average of 2 years of diagnosis. Our
recruitment rate in AMBER is noteworthy given that
breast cancer survivors are asked to complete maximal
aerobic and strength testing, upper body functioning
assessments, DXA scans, blood draws, and numerous
detailed questionnaires within a few months of diagno-
sis. As might be expected, 2 of the main reasons for re-
fusal in AMBER are being overwhelmed/too sick and
out of town/distance. We have attempted to reduce the
number of refusals for out of town survivors by empha-
sizing and accommodating single day visits.
The baseline assessment completion rates in AMBER are
excellent given the nature and timing of the assessments.
For our primary exposure of cardiorespiratory fitness, we
have evaluable data on 86.2 % of participants. The main
reasons for missed or incomplete cardiorespiratory testing
are safety/medical issues and musculoskeletal injuries,
which are difficult to circumvent. All other HRF assess-
ments were completed by over 85 % of participants with
the exception of upper body strength and endurance. Body
composition assessed by DXA scan has been completed by
over 98 % of participants, highlighting the differences be-
tween passive (e.g., DXA, lymphedema) versus physically
demanding (e.g., maximal aerobic and strength) assess-
ments. We are unaware of any other breast cancer survivor
cohort studies that are including HRF assessments beyond
BMI and waist-hip circumference. In AMBER, we have ob-
tained over 98 % baseline completion for BMI compared to
92 % in Pathways [12], 100% in HEAL [13], and 84 % in
LACE [14]. Moreover, we have obtained over 99 % baseline
completion for anthropometrics compared to 92 % in Path-
ways [12].
As noted, the lowest baseline assessment completion
rate is for upper body strength and endurance, which
was completed by just under 80 %. The main reason for
the missed assessments was safety issues (e.g., post-
surgery lifting restrictions) based on the primary sur-
gery and/or immediate reconstructive surgery. These
restrictions occurred more often in Calgary than Ed-
monton because of the different recruitment protocols
in the 2 centers. Specifically, recruitment and testing
was occurring earlier in Calgary, resulting in less recov-
ery time after surgery. To standardize the timing of the
baseline HRF assessments between the 2 centers, the
protocol has been modified to stipulate that strength
testing should occur at least 6 weeks after surgery.
The baseline assessment completion rates for lymph-
edema, upper arm function, peripheral neuropathy, and
blood draws were all over 98 % and did not differ by cen-
ter. Few breast cancer survivor cohort studies have even
attempted to collect such data. Pathways [12] collected
baseline blood from 86 % of participants. As expected, the
relative proportion of blood draws that were performed
pre-surgically versus post-surgically differed by center
with Calgary obtaining over 80 % of its blood draws pre-
Table 1 Baseline assessment completion rate of the first 500
participants in the AMBER Study, Alberta, 2012-2014
Baseline assessments Calgary
(n = 249) n (%)
Edmonton
(n = 251) n (%)
Total
(n = 500) n (%)
Health-related fitness
Cardiorespiratory fitness 211 (84.7 %) 220 (87.6 %) 431 (86.2 %)
Upper body strength 166 (66.7 %) 231 (92.0 %) 397 (79.4 %)
Upper body endurance 164 (65.9 %) 231 (92.0 %) 395 (79.0 %)
Lower body strength 198 (79.5 %) 233 (92.8 %) 431 (86.2 %)
Lower body endurance 194 (77.9 %) 233 (92.8 %) 427 (85.4 %)
Grip strength 240 (96.4 %) 244 (97.2 %) 484 (96.8 %)
Curl-ups 208 (83.5 %) 222 (88.4 %) 430 (86.0 %)
Flexibility 232 (93.2 %) 243 (96.8 %) 475 (95.0 %)
Waist/hip
circumference
248 (99.6 %) 251 (100 %) 499 (99.8 %)
Body composition
(DXA scan)
240 (96.4 %) 250 (99.6 %) 490 (98.0 %)
Clinical data
Lymphedema 244 (98.0 %) 249 (99.2 %) 493 (98.6 %)
Upper arm range of
motion
245 (98.4 %) 251 (100 %) 496 (99.2 %)
Peripheral neuropathy 242 (97.2 %) 251 (100 %) 493 (98.6 %)
Blood samples 249 (100 %) 248 (98.8 %) 497 (99.4 %)
Pre-surgical blood 205 (82.3 %) 24 (10.0 %) 229 (45.8 %)
Post-surgical blood 44 (17.7 %) 224 (89.2 %) 268 (53.6 %)
Questionnaires
BHQ 230 (92.4 %) 248 (98.8%) 478 (95.6 %)
DHQ 228 (91.6 %) 246 (98.0%) 474 (94.8 %)
GHQ 229 (92.0 %) 247 (98.4%) 476 (95.2 %)
PYPAQ 228 (91.6 %) 245 (97.6%) 473 (94.6 %)
Activity monitors
Actigraph GT3X® 213 (85.5 %) 239 (95.2 %) 452 (90.4 %)
ActivPAL® 202 (81.1 %) 239 (95.2 %) 441 (88.2 %)
Activity monitor log 213 (85.5 %) 238 (94.8 %) 451 (90.2 %)
Notes: DXA dual energy x-ray absorptiometry, BHQ Baseline Health Questionnaire,
DHQ Diet Health Questionnaire, GHQ General Health Questionnaire, PYPAQ Past
Year Physical Activity Questionnaire
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surgically compared to just 10 % in Edmonton. This differ-
ence was built into the design of AMBER based on pre-
existing differences in biospecimen banking between
Calgary and Edmonton. Pre-surgical blood collection in
Calgary allows us to collect blood prior to any potential
impacts of surgery and thus provides a “true” baseline
blood profile after breast cancer diagnosis.
In terms of accelerometry, we have obtained useable
data of ≥4 days/week of monitoring for the Actigraph
GT3X® and activPAL® from approximately 90 % of par-
ticipants with slightly lower rates in Calgary. We are un-
aware of any large population-based cancer survivor
cohort studies that have attempted to collect objectively
assessed PA and sedentary behavior (including sitting
time), however, our rate of useable data ≥4 days/week
compares favorably to the 80-85 % reported for women
over 40 years old in the National Health and Nutritional
Examination Survey [15]. The collection of objective
Table 2 Baseline descriptive characteristics of the first 500 participants in the AMBER Study, Alberta, 2012-2014
Baseline characteristics Calgary
(n = 249)
Edmonton (n = 251) Total
(n = 500)
Age at diagnosis (n = 500) 56.4 ± 10.8 54.7 ± 10.3 55.5 ± 10.6
<50 64 (25.7 %) 86 (34.2 %) 150 (30.0 %)
50-59 85 (34.1 %) 78 (31.1 %) 163 (32.6 %)
60-69 71 (29.0 %) 74 (29.5 %) 145 (29.0 %)
70+ 29 (11.7 %) 13 (5.2 %) 42 (8.4 %)
Marital status (n = 471)
Married/common law 154 (68.1 %) 191 (78.0 %) 345 (73.2 %)
Not married 72 (31.9 %) 54 (22.0 %) 126 (26.8 %)
Education (n = 471)
≤High school 51 (22.6 %) 55 (22.4 %) 106 (22.5 %)
≥University 175 (77.4 %) 190 (77.6 %) 365 (77.5 %)
Income (n = 443)
< $50 000 37 (17.5 %) 30 (12.9 %) 67 (15.1 %)
$50 000–$100 000 72 (34.1 %) 77 (33.2 %) 149 (33.6 %)
$100 000–$150 000 34 (16.1 %) 64 (27.6 %) 98 (22.1 %)
> $150 000 68 (32.2 %) 61 (26.3 %) 129 (29.1 %)
Ethnicity (n = 471)
Caucasian 198 (87.6 %) 197 (80.4%) 395 (83.9 %)
Other 28 (12.4 %) 48 (19.6%) 76 (16.1 %)
Menopausal status (n = 448)
Premenopausal 76 (36.2 %) 99 (41.6%) 175 (39.1 %)
Postmenopausal 134 (63.8 %) 139 (58.4%) 273 (60.9 %)
Weight, kg (n = 492) 73.5 ± 16.6 72.4 ± 15.0 72.9 ± 15.8
Body mass index, kg/m2
(n = 492)
27.2 ± 5.7 27.1 ± 5.3 27.2 ± 5.5
Normal weight (<25 kg/m2) 102 (41.8 %) 97 (39.1 %) 199 (40.4 %)
Overweight (25–30 kg/m2) 81 (33.2 %) 88 (35.5 %) 169 (34.3 %)
Obese (>30 kg/m2) 61 (25.0 %) 63 (25.4 %) 124 (25.2 %)
First degree family history of breast cancer (n = 457)
≥ one first degree relative 59 (26.8 %) 62 (26.2 %) 121 (26.5 %)
No first degree relatives 161 (73.2 %) 175 (73.8 %) 336 (73.5 %)
Cancer stage (n = 500)
I (≥TIc) 103 (41.4 %) 108 (43.0 %) 211 (42.2 %)
II 129 (51.8 %) 115 (45.8 %) 244 (48.8 %)
III 17 (6.8 %) 28 (11.2 %) 45 (9.0 %)
Values are means ± SD or n (%) within each study site and overall
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measures of PA and sedentary behavior is a real strength
of AMBER because it will allow us to examine the asso-
ciations of specific daily and weekly patterns of PA and
sedentary behavior with breast cancer outcomes.
We can compare our sample to the broader breast can-
cer survivor population in Alberta and to other breast
cancer survivor cohorts in the United States. Fisher et al.
[16] reported the age and stage distribution of all 14,939
women diagnosed with stage I to III breast cancer in
Alberta between 2002 and 2010. The stage distribution in
the Alberta Cancer Registry was 49 % stage I, 38 % stage
II, and 13 % stage III compared to the AMBER distribu-
tion of 42 % stage I, 49 % stage II, and 9 % stage III. Con-
sequently, our AMBER sample slightly over-represents
stage II and under-represents both stage I and III. These
differences are most likely due to our exclusion of T1a
and T1b cancers (a large portion of stage Is) and the chal-
lenges of recruiting breast cancer survivors initiating neo-
adjuvant chemotherapy (a large portion of stage IIIs).
Although not exactly representative of the stage distri-
bution of breast cancer survivors in Alberta, the stage
distribution in AMBER compares favorably to other
breast cancer survivor cohorts in the United States. For
example, LACE [14] includes 47 % stage I, 50 % stage II,
and only 3 % stage III (all stage IIIas). HEAL [13] in-
cludes 23 % stage 0, 59 % stage I, and only 18 % stage II
and III combined. Finally, excluding a small number of
stage IV cancers, Pathways [12] includes slightly more
stage IIIs than AMBER (11 % versus 9 %) but also more
stage Is (54 % versus 42 %). Consequently, the overall
and breast cancer-specific event rates in AMBER are
likely to exceed the event rates in other established life-
style and breast cancer survivor cohorts.
In terms of the age distribution, the Alberta Cancer
Registry data [16] showed that 28 % of all newly diagnosed
breast cancer survivors were <50 years old, 28 % were 50–
59, 25 % were 60–69, and 19 % were 70+ (excluding survi-
vors over age 80). In AMBER, we have 30 % under 50 years
old, 33 % between 50 and 59, 29 % between 60 and 69,
and 8 % 70+. Consequently, our AMBER sample over-
represents the under 70 age groups and under-represents
the 70+ age group. Moreover, the average age in AMBER
of 56 years is slightly younger than the 60 years reported
in Pathways [12] and LACE [14] and the 58 years reported
in HEAL [13]. Again, this bias towards a younger sample
is probably due to the higher level functioning required
for maximal HRF testing.
Obesity is emerging as a critical issue in cancer treat-
ment and care [17]. AMBER is uniquely positioned to
make a substantial contribution to our understanding of
how obesity affects breast cancer treatment, survivorship,
and outcomes given our inclusion of DXA scans in
addition to the standard height, weight, and circumference
measures. In AMBER, 60 % of breast cancer survivors are
overweight or obese, which compares favorably to the 68
% in Pathways [12] and 61 % in LACE [14]. Moreover, the
HEAL [13] sample has a mean BMI of 26.6 compared to
27.2 in AMBER. The high rate of overweight and obesity
in AMBER will provide substantial power to examine its
complex role in breast cancer survivorship.
AMBER has many important strengths but also some
emerging limitations. The strengths of AMBER include
the prospective cohort design; restriction to ≥ stage 1
(T1c) breast cancer; recruitment soon after diagnosis;
the comprehensive objective assessments of PA, seden-
tary behavior, and HRF using gold standard measures;
the multiple standardized assessment time points; and
the high rate of completion for many baseline assess-
ments. The emerging limitations of AMBER include the
modest eligibility and recruitment rates; the lack of data
on those women who did not consent for research with
the tumor bank or provide a presurgical blood sample;
the lack of data on those women who refused participa-
tion in AMBER; differences between the 2 centers in
the timing and completion rates of some baseline
assessments; and the under-representation of older and
stage III breast cancer survivors. Efforts are ongoing to
improve the eligibility and recruitment rates,
standardize the timing and completion rates of the
baseline assessments between centers, and recruit lar-
ger proportions of older and advanced stage breast can-
cer survivors.
Conclusions
Despite some emerging limitations, AMBER is establish-
ing a cohort that will provide the most comprehensive
and rigorous evaluation of the role of PA, sedentary be-
havior, and HRF in breast cancer survivorship. Once
completed, AMBER will allow for a sophisticated and
detailed analyses of the outcomes, determinants, biologic
mechanisms, and moderators of PA, sedentary behavior,
and HRF for breast cancer outcomes and survivorship.
The data generated may inform phase III randomized
controlled trials on lifestyle and breast cancer outcomes;
and may also inform PA, sedentary behavior, and HRF
guidelines to optimize breast cancer outcomes and qual-
ity of life.
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